Contact the ACC Registration and Housing Center

  • (888) 322-2878
    (toll-free)
  • (847) 996-5822 (International)
  • M-F, 9:00 a.m. - 6:00 p.m. ET
  • acc@experient-inc.com
  • Industry-Expert Theaters
    Expo Hall, #23077 and #23031

    Connect with the experts in the Industry-Expert Theaters as presenters share the latest in cardiovascular practices, services and technologies while you enjoy refreshments or lunch — presentations are conveniently scheduled during the daily breaks.

      Saturday, March 28
      Saturday, March 28

    10:15 a.m. – 11:15 a.m.

    4001. Empowering the Treatment of Heart Failure and Structural Heart Disease
    Theater 1, Expo Hall, #23077
    Sponsored by Abbott

    Heart disease continues to be the leading cause of death in the U.S. with heart failure mortality rate increasing 24% in recent years. It has become increasingly important to recognize when medications alone are not enough and referral to device interventions may be required. In this program, cardiology experts will discuss the latest device advancements and clinical data for MitraClip™ Transcatheter Mitral Valve Repair, CardioMEMS™ HF System, and HeartMate 3™ LVAD therapy.

    • Clinical Challenges in Managing Heart Disease
    • MitraClip™ Therapy Identifying and Treating Mitral Regurgitation
    • CardioMEMS™ HF System – Proven, Proactive, Personalized
    • HeartMate 3™ LVAD Destination Therapy – Real World Evidence Looking Beyond Bridge to Transplantation

    Speakers:
    Tom Heywood, MD (moderator)
    Medical Director, Scripps Advanced Heart Failure and Mechanical Circulatory Support Program Scripps Clinic, La Jolla, CA

    Saibal Kar, MD
    Director of Structural Heart Disease and Research, HCA Healthcare, Los Angeles, CA

    Nir Uriel MD, MSc
    Director of Heart Failure, Heart Transplantation & Mechanical Circulatory Support Programs, New York Presbyterian

    4009. Amgen: Cardiovascular Patient Cases
    Theater 2, Expo Hall, #23031
    Sponsored by Amgen

    Speaker:
    Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA

    12:45 p.m. – 1:45 p.m.

    4002. Selecting a First-Choice Therapy for Systolic HF: The Growing Body of Evidence

    TBA Theater 1, Expo Hall, #23077
    Sponsored by Novartis Pharmaceuticals Corporation

    Speakers:

    Daniel Bensimhon, MD
    Medical Director, Advanced HF & Mechanical Circulatory Support Program, Cone Health, Greensboro, NC

    Gregg C. Fonarow, MD, FAHA, FACC, FHFSA
    Eliot Corday Professor of Cardiovascular Medicine and Science; Director, Ahmanson-UCLA Cardiomyopathy Center; Chief, UCLA Division of Cardiology (Interim); Co-Director, UCLA Preventative Cardiology Program

    Sponsored by Novartis Pharmaceuticals Corporation, and the faculty will be compensated for their time.

    4010. Thinking Beyond HFpEF: The Dizzying Universe of hATTR Amyloidosis
    Theater 2, Expo Hall, #23031
    Sponsored by Alnylam Pharmaceuticals

    Please join our expert panel to learn about the importance of differentiating between hypovolemic and neurogenic orthostatic intolerance in the diagnosis of hereditary transthyretin-mediated (hATTR) amyloidosis, discuss how to recognize key signs and symptoms that may precede diagnosis, and evaluate the cardiac imaging techniques available to help diagnose hATTR amyloidosis.

    12:45 p.m.
    Welcome and Introduction

    12:50 p.m.
    Beyond the Heart: Autonomic Dysfunction in hATTR Amyloidosis

    1:05 p.m.
    Looking Back at hATTR Amyloidosis Red Flags

    1:20 p.m.
    Inside the Viewing Room: Diagnosis of hATTR Amyloidosis Through Cardiac Imaging

    1:40 p.m.
    Q&A

    Speakers:
    Amanda Peltier, MD
    Nashville, USA

    Nitasha Sarswat, MD
    Chicago, USA

    Prem Soman, MD, PhD, FACC
    Pittsburgh, USA

    3:45 p.m. – 4:45 p.m.

    4003. VASCEPA® (icosapent ethyl): Elevating the Standard of Care
    Theater 1, Expo Hall, #23077
    Sponsored by Amarin Pharma, Inc

    There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statin-based standard-of-care therapy in patients with elevated triglycerides. In this program, we will review data from a practice changing trial that provides a new therapeutic option to elevate the current standard of care.

    Speaker:
    Alan S. Brown MD, FACC, FAHA, FNLA, FASPC
    Director, Division of Cardiology & Director of the Lipid Clinic Advocate Lutheran General Hospital

    4011. Jardiance® (empagliflozin) Tablets: Data From the Comprehensive Clinical Development Program
    Theater 2, Expo Hall, #23031
    Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA

    This program will discuss recent data from the ongoing JARDIANCE clinical development program. The presentation will cover efficacy and safety data, as well as the dosing information for JARDIANCE. Attendees will also have the opportunity to ask the faculty questions about the data presented.

    Speaker:
    Robert J. Chilton, DO, FACC, FAHA
    Professor, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas

      Sunday, March 29
      Sunday, March 29

    9:45 a.m. – 10:45 a.m.

    4004. A First-Choice Treatment for the Inpatient Management of Stabilized Systolic HF Patients: An Evidence-Based Approach
    Theater 1, Expo Hall, #23077
    Sponsored by Novartis Pharmaceuticals Corporation

    Speakers:

    Javed Butler, MD, MPH, MBA
    Chairman and Professor, Department of Medicine, University of Mississippi, Jackson, MS

    Patrick McCann, MD
    Clinical Assistant Professor, University of South Carolina School of Medicine, Columbia, SC

    4012. Importance of Real World Evidence in Understanding Current Lipid Management in Patients With ASCVD: A Focus on MI
    Theater 2, Expo Hall, #23031
    Sponsored by Amgen

    Speaker:
    Nihar R. Desai, MD, MPH

    12:45 p.m. – 1:45 p.m.

    4005. TEGSEDI®: Targeting the Source of Polyneuropathy From Hereditary ATTR Amyloidosis
    Theater 1, Expo Hall, #23077
    Sponsored by Akcea Therapeutics

    An innovative patient-moderated panel, including a Cardiologist and a Neurologist with discussion on how early diagnosis and treatment are imperative in managing hATTR amyloidosis with polyneuropathy. In addition these experts share various perspectives on a unique treatment option and its effects on progression of neuropathy and patient quality of life.

    Speakers:
    Said Beydoun, MD
    Professor, University of Southern California

    Richard Wright, MD
    Pacific Heart Institute

    4013. Amgen: Cardiovascular Patient Cases
    Theater 2, Expo Hall, #23031
    Sponsored by Amgen

    Speaker:
    Alan S. Brown, MD, FACC, FAHA, FNLA

    3:45 p.m. – 4:45 p.m.

    4006. Heart Failure With Preserved Ejection Fraction: Current Perspectives and Opportunities to Optimize Care Surrounding Hospitalization
    Theater 1, Expo Hall, #23077
    Sponsored by Novartis Pharmaceuticals Corporation

    Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of heart failure cases, and the prevalence of HFpEF is increasing at a rate of 1% per year. HFpEF management is complicated by diverse clinical phenotypes, complex pathophysiology, and a clinical course that often includes hospitalization. Hospitalizations are associated with increased risk of mortality and rehospitalization in patients with HFpEF. Therefore, early recognition of worsening symptoms that often precipitate hospitalization is critical. This program will review current perspectives on HFpEF, including disease burden, clinical manifestations, and underlying pathophysiology, and describe opportunities for optimizing care surrounding hospitalization and worsening HFpEF.

    Sponsored by Novartis Pharmaceuticals Corporation, and the faculty will be compensated for their time.

    Speaker:
    Sanjiv Shah, MD, FAHA, FACC, FASE
    Stone Professor of Medicine, Director of Research, Bluhm Cardiovascular Institute, Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine

    4014. New Data, Guidelines, and What It Means For Managing LDL-C in Your Recent MI Patients
    Theater 2, Expo Hall, #23031
    Sponsored by Amgen

    Speakers:
    Manos S. Brilakis, MD, PhD

    Payal Kohli, MD, FACC

      Monday, March 30
      Monday, March 30

    9:45 a.m. – 10:45 a.m.

    4007. Managing LV Dysfunction and SCD Risk — Optimizing Medical Therapy for HF Patients
    Theater 1, Expo Hall, #23077
    Sponsored by ZOLL

    4015. Confronting CVD in Patients With T2D: A Review of the Pathophysiologic Links and Management Strategies
    Theater 2, Expo Hall, #23031
    Sponsored by Novo Nordisk

    This program reviews the links between cardiovascular disease and T2D and how current guidelines have made this a critical feature of how patients are managed. Details regarding their pathophysiologic links are discussed using a series of infographics which show how inflammation and endothelial dysfunction play key roles in the development of CVD and how T2D amplifies this process. Lastly, the significance of CVOTs and their impact on the updated ADA and ACC guidelines are also discussed.

    Speaker
    Joshua M. Stolker, MD
    STEMI Director, Mercy Heart and Vascular, Washington, Missouri; Adjunct Associate Professor, Saint Louis University, St. Louis, Missouri

    11:30 a.m. – 12:30 p.m.

    4008. A New Approach for Managing Lipids: A Novel, Oral, Nonstatin Therapy for Lowering LDL-C
    Theater 1, Expo Hall, #23077
    Sponsored by Esperion

    The session will cover the following information:

    • Cardiovascular disease and increasing death rates
    • Unique mechanism of action of bempedoic acid
    • Pooled efficacy data for bempedoic acid
    • Pooled safety data for bempedoic acid
    • Overview slide of the CLEAR Outcomes trial

    Speaker:
    Pam R. Taub, MD, FACC, FASPC
    Associate Professor of Medicine, UC San Diego Health System, La Jolla, CA

    4016. Title to be Announced
    Theater 2, Expo Hall, #23031
    Sponsor to be announced


    Schedule is current as of Feb. 12, 2020, and is subject to change. Please check back for updates.

    *Industry-Expert Theater presentations are not part of ACC.20/WCC, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

    ADVERTISEMENT
    Have a question about ACC.20/WCC?
    Ask Artie, our show expert chatbot.
    ACC Logo
    ACC.20/WCC on Social Media:
          
    2019 American College of Cardiology Foundation. Visit ACC.org
    Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us